Want to see GB:STX full AI Analyst Report?
Top Page
Shield Therapeutics
(LSE:STX)
Select Model
Select Model
Rating:44Neutral
Price Target:
6.00 p
▲(23.71% Upside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial resilience: ongoing losses, continued cash burn, and negative equity despite improving revenue and margin trends. Technicals are mixed (better short-term momentum but weak longer-term trend and negative MACD), while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue Growth
The sharp revenue increase indicates stronger Accruer/Feraccru adoption and expanding commercial traction. Sustained prescription demand can improve operating leverage as the company scales its existing product and market infrastructure.
Negative Factors
Negative Equity
Negative equity indicates that liabilities exceed recorded assets, limiting financial flexibility and reducing resilience to setbacks. It may leave Shield dependent on external funding, creating ongoing refinancing or dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp revenue increase indicates stronger Accruer/Feraccru adoption and expanding commercial traction. Sustained prescription demand can improve operating leverage as the company scales its existing product and market infrastructure.
Read all positive factors
Shield Therapeutics (STX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£65.26M
Dividend YieldN/A
Average Volume (3M)3.75M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth36.19%
EPS Growth60.75%
CountryUK
Employees61
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,069,911,300
10 Day Avg. Volume3,248,013
30 Day Avg. Volume3,750,221
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-5.76
Price to Sales (P/S)1.71
P/FCF Ratio-9.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£73.55M
Shield Therapeutics Business Overview & Revenue Model
Company Description
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral...
How the Company Makes Money
Shield Therapeutics makes money primarily from the commercialization of its lead product, Accrufer®/Feraccru® (ferric maltol). The main revenue streams are: (1) Product sales: revenue generated from selling Accrufer/Feraccru in markets where the c...
Shield Therapeutics Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
27
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.51M | 50.74M | 32.18M | 16.54M | 4.48M | 1.52M |
| Gross Profit | 29.59M | 22.38M | 13.22M | 5.09M | 2.00M | -1.67M |
| EBITDA | -3.28M | -9.16M | -21.26M | -38.28M | -46.07M | -17.69M |
| Net Income | -2.23M | -18.03M | -26.61M | -33.29M | -40.44M | -19.34M |
Balance Sheet | ||||||
| Total Assets | 53.92M | 65.24M | 57.42M | 48.80M | 22.07M | 44.41M |
| Cash, Cash Equivalents and Short-Term Investments | 8.39M | 11.63M | 7.02M | 17.63M | 2.82M | 12.12M |
| Total Debt | 25.03M | 30.15M | 26.34M | 25.80M | 6.10M | 156.00K |
| Total Liabilities | 71.04M | 80.32M | 58.74M | 33.77M | 16.65M | 3.38M |
| Stockholders Equity | -17.11M | -15.08M | -1.32M | 11.79M | 5.43M | 40.69M |
Cash Flow | ||||||
| Free Cash Flow | -12.31M | -8.83M | -8.80M | -50.65M | -20.14M | -18.80M |
| Operating Cash Flow | -12.26M | -8.81M | -8.77M | -46.93M | -18.25M | -16.74M |
| Investing Cash Flow | 949.89K | -306.29K | -2.37M | -3.07M | -1.70M | -2.05M |
| Financing Cash Flow | 9.09M | 13.75M | 5.26M | 62.77M | 7.71M | 27.58M |
Shield Therapeutics Technical Analysis
Neutral
4.85
Price Trends
5.41
Positive
6.35
Negative
8.01
Negative
Market Momentum
0.03
Negative
70.34
Negative
86.39
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Neutral. The current price of 4.85 is above the 20-day moving average (MA) of 4.46, below the 50-day MA of 5.41, and below the 200-day MA of 8.01, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 70.34 is Negative, neither overbought nor oversold. The STOCH value of 86.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:STX.
Shield Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £78.69M | 15.07 | 7.82% | ― | ― | ― | |
70 Outperform | £3.34B | 12.19 | 15.05% | 3.91% | 2.48% | 3.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £65.26M | -7.31 | 64.57% | ― | 36.19% | 60.75% | |
42 Neutral | £360.95M | -5.66 | 409.00% | ― | 2.94% | -32.00% |
* Healthcare Sector Average
GB:STX
Shield Therapeutics
5.30
-1.65
-23.74%
GB:AGY
Allergy Therapeutics
5.60
-2.90
-34.12%
GB:HIK
Hikma Pharmaceuticals
1,615.00
-45.55
-2.74%
GB:VLG
Venture Life
65.70
5.70
9.50%
Shield Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Shield Therapeutics Takes Full Control of U.S. ACCRUFeR Business to Boost Profitability
Positive
Aug 27, 2026
Shield Therapeutics has struck an agreement with Viatris under which it will assume full commercial responsibility for ACCRUFeR® in the United States, its largest and fastest-growing market, from the end of September 2026. The deal transfers ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Shield Therapeutics narrows losses as ACCRUFeR® growth and global milestones lift H1 revenue
Positive
Aug 20, 2026
Shield Therapeutics reported unaudited interim results showing group revenues of $30.4 million for the first half of 2026, up 42% year-on-year, driven by U.S. sales of ACCRUFeR® and a sharp rise in ex-U.S. milestones and royalties. The group ...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates total voting rights and underscores global iron therapy push
Positive
Aug 3, 2026
Shield Therapeutics has confirmed that its issued share capital comprises 1,069,911,197 ordinary shares of 1.5p each, all carrying equal voting rights and with no shares held in treasury. This disclosure updates investors on the total voting right...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Shield Therapeutics grows H1 revenue, pivots commercial strategy and appoints new CFO
Positive
Jul 30, 2026
Shield Therapeutics reported unaudited H1 2026 revenues of $30.4M, up from $21.5M a year earlier, helped by a $7.9M milestone payment from its Chinese partner ASK and higher royalties, keeping the group profitable in the half. Q2 net revenue was $...
Business Operations and StrategyProduct-Related Announcements
Shield’s pediatric trial backs ferric maltol in childhood iron deficiency anemia
Positive
Jul 28, 2026
Shield Therapeutics has reported that results from its Phase 3 FORTIS pediatric trial of ferric maltol have been published in the journal Pediatric Drugs, reinforcing the drug’s role in managing iron deficiency anemia in children. The study ...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics issues shares under performance plan while keeping other incentive schemes unchanged
Positive
Jun 30, 2026
Shield Therapeutics has reported its latest six-month block listing update for several employee and incentive share schemes, covering the period from 1 January to 30 June 2026, with minimal changes to most plans. Across three of its schemes—...
Business Operations and StrategyShareholder Meetings
Shield Therapeutics Secures Strong Shareholder Backing at 2026 AGM
Positive
Jun 18, 2026
Shield Therapeutics reported that all 14 resolutions put to shareholders at its 2026 annual general meeting were approved, with each motion receiving more than 99% of votes cast in favour and minimal opposition. The strong backing for both ordinar...
Business Operations and StrategyRegulatory Filings and Compliance
Shield Therapeutics updates share capital as iron deficiency franchise expands globally
Positive
May 29, 2026
Shield Therapeutics has confirmed that its issued share capital currently comprises 1,069,524,125 ordinary shares of 1.5p each, all carrying equal voting rights, with no shares held in treasury. This updated share count provides investors with the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.